#Sweden #Stockholm #BioArctic #Lilly #BrianTransporter

BioArctic and Lilly: A Groundbreaking Collaboration in Neurodegenerative Disease Research

BioArctic AB, a pioneering biopharmaceutical firm based in Sweden, has made headlines with its latest strategic partnership with Eli Lilly and Company. Announced on June 22, 2026, this collaboration focuses on developing innovative treatments for neurodegenerative disorders by joining BioArctic's proprietary BrainTransporter™ technology with a Lilly drug candidate. The implications of this partnership could be significant, potentially transforming treatment options for patients grappling with such debilitating conditions.

The Financial Framework of the Agreement

As part of this comprehensive agreement, BioArctic stands to receive an upfront payment amounting to USD 30 million. Beyond this initial sum, the deal has the potential to yield milestone payments reaching as high as USD 770 million, an indicator of the ambitious goals set for this collaboration. Additionally, BioArctic will earn tiered royalties on the global sales of the drug candidate if it successfully reaches the market, exemplifying the lucrative nature of this partnership.

A Focus on the BrainTransporter™ Technology

At the heart of this collaboration is BioArctic's BrainTransporter technology, designed to facilitate the entry of therapeutic agents into the brain. This mechanism utilizes the transferrin receptor (TfR) to enhance drug delivery, a critical factor in improving treatment efficacy while ensuring a favorable safety profile and dosage convenience. Through this agreement, BioArctic will create a new drug candidate that effectively combines its BrainTransporter technology with a Lilly proprietary molecule.

Lilly, on its part, will take the lead on the global development and commercialization of the combined product, ensuring that the collaboration leverages both parties' strengths in the industry. Gunilla Osswald, CEO of BioArctic, expressed her enthusiasm saying, "I'm excited by today's announcement and proud that a large pharmaceutical company sees potential in our proprietary BrainTransporter technology. Lilly shares our ambition to do more for patients with severe neurological disorders, and this collaboration is a testament to that."

Expanding Opportunities

This new partnership marks the fourth collaboration for BioArctic leveraging its BrainTransporter technology, reflecting the firm’s growing influence in the biopharmaceutical landscape. Despite entering into multiple agreements, BioArctic retains rights to use the BrainTransporter technology outside the confines of these collaborations, which opens doors for further partnerships across various therapeutic areas, enhancing the scope and versatility of their innovations.

BioArctic’s BrainTransporter platform is not only limited to the current collaboration; it has the potential to revolutionize how numerous therapies are delivered to the brain, thereby presenting a multitude of prospective partnerships in the future.

The Larger Picture

BioArctic’s mission aligns with its long-standing commitment to research and development in neurodegenerative diseases. The company recently gained recognition for creating Leqembi® (lecanemab), noted as the world’s first proven drug to decelerate the progression of early Alzheimer’s disease. Such breakthroughs underscore BioArctic's capabilities and reaffirm its role as a trailblazer in the biopharma sector.

In conclusion, the collaboration between BioArctic and Lilly represents not only a significant financial commitment but an essential stride towards addressing the urgent medical needs presented by neurodegenerative diseases. As this partnership unfolds, it holds the promise of bringing innovative therapies to market, aimed at improving the lives of countless patients worldwide.

Before proceeding with the research and development undertaken within this partnership, it is essential to note that investigational agents are still in development phases and efficacy or safety outcomes cannot be guaranteed. Regulatory approvals remain a crucial step in this journey. For continuous updates, stakeholders are encouraged to stay engaged with both companies.

For further inquiries, contacts at BioArctic include Oskar Bosson, VP of Communications, and Jenny Ljunggren, Manager of External Communications and Investor Relations.